



ASX / Media Release
21 June 2024

Invex Receives £633k R&D Tax Rebate from UK Government

Invex Therapeutics Ltd (Invex, ASX:IXC, or the Company) a biopharmaceutical company focused on the development and commercialisation of Presendin™ (sustained release Exenatide) for neurological conditions relating to raised intracranial pressure today announces the receipt of £633k (approximately A\$1.2 million) to the Company's wholly owned UK subsidiary from the UK government for eligible R&D expenditures made by Invex during the 2023 financial year.

Dr Thomas Duthy, Executive Director of Invex Therapeutics said "The 2023 financial year represented a significant R&D spend for the organisation, predominately associated with the IIH EVOLVE Phase III clinical trial. We are pleased to have finally received these funds, which have partially offset our gross R&D spend for that year."

- ENDS -

This release dated 21 June 2024 has been authorised for lodgement to ASX by the Board of Directors of Invex Therapeutics.

For more information, please contact:

Company/Investors

Dr Thomas Duthy
Executive Director
tduthy@invextherapeutics.com
+61 402 493 727

Media

Margie Livingston
Ignite Communications
margie@ignitecommunications.com.au
+61 438 661 131

To subscribe to Invex email alerts, please visit www.invextherapeutics.com and follow us on Twitter **@InvexThera_ASX**

About Invex Therapeutics Ltd

Invex is a biopharmaceutical company focused on the repurposing of an already approved drug, Exenatide, for efficacious treatment of neurological conditions derived from or involving raised intracranial pressure. Invex has trademarked its repurposed Exenatide as Presendin™. www.invextherapeutics.com.